Huntington National Bank Editas Medicine, Inc. Transaction History

Huntington National Bank

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 11, 2023	BUY	$6.36 - $11.47 $203 - $367	32 New	32 $0
Q4 2021 Jan 21, 2022	SELL	$26.55 - $40.57 $3,717 - $5,679	-140 Reduced 25.69%	405 $10,000
Q3 2021 Oct 28, 2021	BUY	$39.27 - $72.94 $5,497 - $10,211	140 Added 34.57%	545 $22,000
Q4 2020 Jan 11, 2021	BUY	$27.07 - $84.35 $812 - $2,530	30 Added 8.0%	405 $28,000
Q1 2020 Apr 27, 2020	BUY	$14.88 - $32.78 $5,580 - $12,292	375 New	375 $7,000

248

57M

410K

394K

Ticker EDIT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,737,200
Market Cap $90M
Description
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...

Get notified when there are updates to the investment portfolio of Huntington National Bank, based on Form 13F filings with the SEC.

Stay updated on Huntington National Bank with notifications on news.